Sonal Mehra MD, DM
Centre for Rheumatology Arthritis and Spine, Noida
A. Lithium
B. Hydroxychloroquine
C. Propranolol
D. Fluconazole
A. Increased cAMP levels
B. Increased cGMP levels
C. Decreased nitric oxide production
D. Enhanced calcium influx into cell
A. Increased bleeding due to small sized platelets
B. Recurrent bacterial, viral, and fungal infections
C. Eczema
D. Asthma
A. Immunodeficiencies with hyper IgM
B. X-Linked Agammaglobulinemia (XLA)
C. DiGeorge syndrome (thymic hypoplasia)
D. Selective immunoglobulin deficiencies (IgM, IgG, IgA)
A. One
B. Two
C. Three
D. Four
A. Up to 10%
B. Up to 20%
C. Up to 40%
D. Up to 80%
A. Cancer rates are similar between 5-mg and 10-mg daily dosing of tofacitinib.
B. Cancer rates were significantly higher for JAK inhibitors compared with placebo.
C. Cancer rates for tofacitinib increased throughout use.
D. Cancer rates for tofacitinib increased throughout use.
A. Chronic spontaneous urticaria
B. Allergic asthma
C. Sjogren’s syndrome
D. Psoriatic Arthritis
A. Cytokine-release
B. IgE-mediated
C. Infusion reactions
D. Serum sickness-like
A. Hypocalcemia
B. History of stroke or myocardial infarction in the past year
C.Renal Impairment
D. Hypersensitivity
01. D
02. B
03. D
04. C
05. B
06. A
07. A
08. D
09. D
10. C